• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Myoview receives approvable letter

Article

Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based

Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based imaging productand will compete with Du Pont Merck's Cardiolite agent. Medi-Physicswill emphasize the fast clearance of Myoview as well as the product'sease of use compared to thallium agents. Final FDA approval isexpected within a few months, according to the company.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.